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Abstract
Background: A number of researches have evaluated the association between the ABCB1 polymorphism and the
lipid-lowering response of statins, but the results have been inconclusive. To examine the lipid-lowering efficacy
and safety associated with the ABCB1 C3435T polymorphism in hypercholesterolemic patients receiving statin, all
available studies were included in this meta-analysis.
Methods: A systematic search for eligible studies in the Cochrane library database, Scopus and PubMed was
performed. Articles meeting the inclusion criteria were comprehensively reviewed, and the available data were
accumulated by the meta-analysis.
Results: The results indicated that the comparisons of CC+CT vs. TT were associated with a significant elevation of
the serum HDL-C levels after statin treatment (CC+CT vs. TT: MD, 2.46; 95 % CI, 0.36 to 4.55; P = 0.02), and the ABCB1
C3435T variant in homozygotes was correlated with decreases in LDL-C (CC vs. TT: MD, 2.29; 95 % CI, 0.37 to 4.20;
P = 0.02) as well as TC (CC vs. TT: MD, 3.05; 95 % CI, 0.58 to 5.53; P = 0.02) in patients treated with statin. However,
we did not observe a significant association in the TG group or an association between other genetic models
serum lipid parameters. In addition, statin treatment more than 5 months led to a higher risk of muscle toxicity.
Conclusions: The evidence from the meta-analysis demonstrated that the ABCB1 C3435T polymorphism may
represent a pharmacogenomic biomarker for predicting treatment outcomes in patients on statins and that statin
treatment for more than 5 months can increase the risk of myopathy.
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Introduction
Cardiovascular diseases are the leading cause of death
worldwide, and atherosclerosis due to lipid metabolism
is one of the main determinants of cardiovascular risk
[1]. Statins, which inhibit 3-hydroxy-3-methylglutaryl co-
enzyme A reductase (HMG-CoA reductase) are effective
at reducing atherosclerosis and cardiovascular risks in
clinical practice by lowering the levels low-density lipo-
protein cholesterol (LDL-C) and total triglycerides (TG)
[2–4]. However, the pharmacodynamic response to statins
varies greatly among patients [5]. Although the mecha-
nisms have not been fully clarified, genetic polymorphisms
may play an important role in individual susceptibility to
drug response, including the ABCB1 C3435T (rs1045642)
genetic variant.
The ABCB1 (adenosine triphosphate -binding cassette,
sub-family B, member 1) gene, which also called multi-
drug resistance 1 gene (MDR1), encodes the intestinal
efflux transporter P-glycoprotein, which has been associ-
ated with the transport of cellular lipids and drugs [6].
More than 50 single-nucleotide polymorphisms (SNP) in
the ABCB1 gene, located at 7, p21-21.1 [7], have been
described in the literature. Among them, ABCB1 C3435T
(rs1045642) is the extensively investigated, and many
studies have shown that the ABCB1 C3435T genotype
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influences ability of P-glycoprotein to direct the absorp-
tion of statins [8].
Both the lipid-lowering response of statin and their
safety has been investigated. Kajinamietal. [9] first ana-
lyzed the effect of the C3435T polymorphism on clinical
outcomes in patients receiving atorvastatin and found
that the C3435T polymorphism was significantly and in-
dependently related to a smaller reduction in LDL-C
and a larger increase in high-density lipoprotein choles-
terol (HDL-C) relative to variant allele carriers in a
gender-specific manner. One study [10] reported that the
ABCB1 C3435T polymorphism differed statistically be-
tween the ADR (muscle toxicity) and non-ADR groups
treated with simvastatin. However, the results from differ-
ent studies [9–16] have been inconsistent. Therefore, we
performed a meta-analysis to determine the relationship
between the ABCB1 C3435T polymorphism and the lipid-
lowering efficacy and safety of statins.
Methods
Literature search
Three electronic databases (PubMed, Scopus and the
Cochrane library) were comprehensively searched. The
latest search was updated in February 2015 with the fol-
lowing terms: statin, ABCB1, MDR1, multidrug resistance,
polymorphism, myopathy, myositis, and rhabdomyolysis.
Fig. 1 Flow diagram of the trial selection process
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All the eligible studies were retrieved, and the bibliograph-
ies of the eligible studies and previous meta-analyses were
checked for additional relevant articles.
Inclusion criteria
Studies that meet the following criteria were included:
(1) published in English, (2) case- control studies on
lipid-lowering therapy, (3) the evaluation of the ABCB1
C3435T polymorphism, the lipid-lowering efficacy and
safety in patients receiving statin, (4) the availability of
the genotype frequency in studied population, and (5)
available data to calculate a mean difference (MD) or
P-value with a 95 % confidence interval (CI).
Data extraction
Two reviewers reviewed all studies carefully, extracted the
data independently, and reached a consensus on all as-
pects. The following information was obtained from each
study: the first author’s name, the publication date, the
country of studied population, sex, age, follow-up period,
treatment protocol, serum lipids parameters, myopathy in-
cidence, statin, and gene information.
Study outcomes
Two endpoints—the lipid-lowering efficacy and safety—were
studied. The efficacy was evaluated by the change in
TC (total cholesterol), TG, HDL-C, and LDL-C after
statin treatment. The lipid-lowering safety in this study
was reflected in the number of adverse effects of
muscle toxicity, which comprised myalgia, myopathy,
rhabdomyolysis or statin-induced elevations in serum
Creatinekinase(CK) [17].
Statistical analysis
The observed genotype frequencies in the controls were
compared with the expected genotype frequencies using
the Hardy-Weinberg equilibrium (HWE). The mean dif-
ference (MD) and 95 % confidence interval (CI) in each
study was used to assess the strength of the association
between the ABCB1 C3435T polymorphism and lipid-
lowering efficacy and safety in patients who received sta-
tin treatment. The pooled MDs were assessed for the
dominant genetic model (CT+TT vs.CC), recessive gen-
etic model (TT vs. CC+CT) and homozygote compari-
son (TT vs. CC) according to the method reported by
Woolf [18]; significance was evaluated using the Z-test.
Heterogeneity between studies was examined through the
use of the χ2-based Q statistic test and was considered sig-
nificant if p <0.1 [19]. The I2statistic was used to efficiently
test for the heterogeneity [20]. If the effects appeared to
be homogeneous, the fixed-effect method was used.
Otherwise the random-effect model was adopted.
The heterogeneity was tested by subgroup analyses. Sen-
sitivity analyses were performed to identify the potential
influence of each study set on the pooled MDs by the se-
quential omission of individual studies. Publication bias
was also detected by the funnel plot, and the symmetry of
the plot distribution indicated the absence of publication
bias [21]. All statistical tests were conducted using Review
Manager (v.5.1, The Cochrane Collaboration), and were
Table 1 Main characteristics of studies included on lipid-lowering therapy in the meta-analysis
Genotype













20 45 32 0.570
Hoenig [15] 2011 Australia Patients recruited with
CAD, ischemic stroke,
or CAD risk-equivalents






















36 60 42 0.130
Rodrigues [13] 2005 Brazil Hypercholesterolemia
patients




19 36 14 0.684
Rosales [12] 2012 Chile Hypercholesterolemia
patients













19 20 11 0.206





25 65 40 0.878
NA Not applicable, HWE Hardy-Weinberg equilibrium, TC Total cholesterol, LDL-C Low-density-lipoprotein cholesterol, HDL-C High-density-lipoprotein cholesterol,
TG Triglycerides
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A total of 140 studies on the ABCB1 C3435T polymorph-
ism and the lipid-lowering efficacy and safety of statins
were identified, and 23 replicated studies were excluded.
Additionally, 24 reviews, 1 meta-analysis, 2 case reports
and 4 studies not involving human beings were excluded.
Meanwhile, 64 irrelevant studies were excluded after
reviewing the title and abstract. Furthermore, seven stud-
ies were excluded because of their insufficient genetic in-
formation, and seven trials were excluded because the
serum lipid parameters (TC, TG, HDL-C, and LDL-C)
and the number of cases of myopathy were not available.
Finally, eight studies, including seven studies (930 pa-
tients) of the lipid-lowering efficacy and three of statin-
associated myopathy (58 cases and 239 controls), met the
inclusion criteria (Fig. 1). The characteristics of the in-
cluded studies are summarized in Table 1 and Table 2. All
the studies were performed on a representative sample of
the target group. Various statin treatment protocols were
applied, including simvastatin 20 mg/day [10], atorvastatin
80 mg/day [15], atorvastatin arm 40 mg/day [14], and
atorvastatin arm 10 mg/day [9, 12, 13], among others
(atorvastatin, rosuvastatin or simvastatin) which we could
not be determined precisely based on the original articles
[11, 16]. The frequencies of the genotypes in each study
(Tables 1 and 2) all followed the HWE.
Meta-analysis results
Association with lipid-lowering therapy
HDL-C The comparison of CC+CT vs. TT was associ-
ated with a significant elevation in the serum HDL-C
levels upon statin treatment (CC+CT vs. TT: MD, 2.46;
95 % CI, 0.36 to 4.55; P = 0.02; I2 = 22 %; Fig. 2 and
Table 3). No significant relationship between the change
in the serum HDL-C level and other genetic models of
the ABCB1 C3435T polymorphism were observed, and
no heterogeneity was identified.
LDL-C Seven studies provided data on LDL-C levels,
and the heterogeneity was low for all comparisons. The
overall meta-analysis demonstrated that LDL-C lowering
effects were associated with the ABCB1 C3435T vari-
ation in homozygotes (CC vs. TT: MD, 2.29; 95 % CI,
0.37 to 4.20; P = 0.02; Fig. 3 and Table 3).
Table 2 Main characteristics and genotype of studies included on myopathy due to statin treatment in the meta-analysis
Case Control




Treatment protocal The definition of the case CC CT TT CC CT TT HWE
Fiegenbaum
[10]
2005 Brazil 25.3 59.2 ± 10.7 6 months simvastatin 20 mg/d Myalgia 5 10 0 21 46 32 0.557
Hoenig [15] 2011 Australia 79 67.6 ± 10 6 weeks atorvastatin 80 mg/d Myalgia 1 2 7 18 46 43 0.349






in serum CK of >3 × UNL
4 17 12 11 17 5 0.707
NA Not applicable
Fig. 2 The association of the ABCB1 C3435T polymorphism with the pooled fix-effects-based mean difference of the change in HDL-C after statin
treatment. Comparison: CC vs. CT+TT
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TC When all eligible studies were pooled, the homozy-
gous ABCB1 C3435T polymorphism was correlated with
decreased TC levels in patients on statin treatment (CC
vs. TT: MD, 3.05; 95 % CI, 0.58 to 5.53; P = 0.02 Fig. 4 and
Table 3). No between-study heterogeneity was detected.
TG As described in Table 3, although no heterogeneity
could be identified, the meta-analysis illustrated that the
association between the change in serum TG after lipid-
lowering therapy and the ABCB1 C3435T variation was
not significant (CC vs. CT+TT: MD, 0.1; 95 % CI, −3.99 to
4.18; P = 0.96; CC+CT vs. TT: MD, 1.14; 95 % CI, −2.97 to
5.26; P = 0.59; CC vs. TT: MD, 1.51; 95 % CI, −3.68 to
6.70; P = 0.57).
Association with myopathy
When the three eligible studies were pooled, the associ-
ation between statin-related myopathy and the ABCB1
C3435T variation was not significant. The I2 statistic in-
dicated between-study heterogeneity (Table 4).
The effect of the ABCB1 C3435T polymorphism was
further evaluated in a stratification analyses according to
the treatment duration. The ABCB1 C3435T poly-
morphism was found to be associated with a risk of my-
opathy in patients treated with statins more than
5 months in four models (C vs. T: OR, 0.42; 95 % CI,
0.23 to 0.75; P = 0.004; CC vs. TT: OR, 0.20; 95 % CI,
0.06 to 0.70; P = 0.01; CC+CT vs. TT: OR, 0.30; 95 % CI,
0.12 to 0.75; P = 0.01; CC vs. CT+TT: OR, 0.33; 95 % CI,
0.11 to 0.98; P = 0.05). Meanwhile, the between-study
heterogeneity in the subgroup was decreased (Table 4).
Test of heterogeneity
No significant heterogeneity was observed in three genetic
comparisons with respect to HDL, LDL, TC, or TG. How-
ever, significant heterogeneity was present in all the four
genetic models of the association of ABCB1 C3435T
(Table 4) with myopathy. We evaluated the source of het-
erogeneity based on the treatment protocol. When we
stratified the trials by treatment duration, the heterogen-
eity was not obvious in the subgroup treated for more
than 5 months (Table 4).
Sensitivity analysis
Sensitivity analysis was performed in the genetic model
producing the positive results. For the lipid-lowering
comparisons, the significance of the pooled MDs was
not significantly affected by the omission of the individ-
ual studies with the exception of one study [10] in the
TC and LDL groups as well as in the female subgroup of
Kajinami’s study [9] in the LDL and HDL-C group.
Given the limited number of studies on statin-associated
myopathy, we were unable to perform the sensitivity
analysis in this section.
Publication bias
A funnel plot was created to assess the publication bias
of our included studies. As indicated in Figs. 5, 6 and 7,
Table 3 The ABCB1 C3435T polymorphism on lipid-lowering therapy
CC vs. CT+TT CC+CT vs. TT CC vs. TT
Variables OR (95 % CI) Pa P OR (95 % CI) Pa P OR (95 % CI) Pa P
TC 1.36(−0.24,2.95) 0.64 0.09 1.33(−0.11,2.77) 0.45 0.07 2.29(0.37,4.20) 0.76 0.02
HDL-C 0.81(−1.48,3.11) 0.62 0.49 2.46(0.36,4.55) 0.25 0.02 2.44(−0.35,5.24) 0.39 0.09
LDL-C 1.79(−0.24,3.83) 0.31 0.08 1.31(−0.56,3.18) 0.29 0.17 3.05(0.58,5.53) 0.72 0.02
TG 0.10(−3.99,4.18) 0.96 0.96 1.14(−2.97,5.26) 0.84 0.59 1.51(−3.68,6.70) 0.91 0.57
ap value of Q-test for heterogeneity test
Fig. 3 The association of the ABCB1 C3435T polymorphism with the pooled fix-effects-based mean difference of the change in LDL-C after statin
treatment. Comparison: CC vs. TT
Su et al. Lipids in Health and Disease  (2015) 14:122 Page 5 of 10
the asymmetry was not statistically significant. There-
fore, no significant publication bias was detected.
Discussion
Cholesterol-lowering therapy is a keystone in the pri-
mary and secondary prevention of CVD [22]. Statins,
which are HMG-CoA reductase inhibitors, are used to
improve the lipid profile in dyslipidemic patients. The
ABCB1 gene is only involved in cellular drug excretion
[23] and the absorption of some drugs (for example clo-
pidogrel [24]) but also possesses other functions: choles-
terol redistribution [25]; intestinal cholesterol re-
absorption [26]; regulation of cholesterol cellular traf-
ficking; and cholesterol redistribution in cholesterol-rich
microdomains of the cell membrane [27, 28]. Hence, the
ABCB1 gene and its polymorphisms may play vital roles
in lipid-lowering response of statins. On the basis of
varying response in the lipid-lowering efficacy and safety
profiles, several genetic studies have been performed to
evaluate the association between the ABCB1 C3435T
polymorphism and the lipid-lowering response in patients
on statin treatment, but the results are inconclusive. There
is no published GWAS studying the association examined
in this meta-analysis. A former meta-analysis [29] re-
ported that there were no significant differences in the ef-
ficacy of statin therapy between the “CC” and “CT+TT”
groups.
In the present meta-analysis, we included the latest re-
search and conducted the study more meticulously than
past studies, including different genetic models and
more detailed data that the former meta-analysis had
not collected; our analysis produced some significant re-
sults. First, this meta-analysis indicated that the reduc-
tion in LDL-C and TC levels was associated with the
ABCB1 C3435T variation in homozygotes. Second, indi-
viduals of genotype CC+CT were more likely to exhibit
an elevation in serum HDL-C upon statin treatment.
However, no significant association in the TG group and
other genetic models was detected with respect to the
above serum lipid parameters. The results are inconsist-
ent with those of the previous study. Although the
between-study heterogeneity in the above comparison
was very limited, it should also be noted. In addition to
genetic polymorphisms, many factors can inference the
results of this research, including the following: differ-
ences in ethnicity, age, gender, genotyping method, study
period, the primary clinical characteristics, and the treat-
ment protocol (the type of statin, the dose, and the treat-
ment duration). Despite the best effort to perform
subgroup analyses according to diverse variables, no sig-
nificant outcome was identified. Recently, an investiga-
tion reported that rosuvastatin (20 mg/day) is more
effective with respect to the ability to increase HDL-C
levels than atorvastatin (80 mg/day) in patients with ST
elevation myocardial infarction (STEMI) [30]. Hence,
Fig. 4 The association of the ABCB1 C3435T polymorphism with the pooled fix-effects-based mean difference in TC levels after statin treatment.
Comparison: CC vs. TT
Table 4 The total and stratified analysis of the ABCB1 C3435T polymorphism on myopathy due to statin treatment
Myalgia Genotype OR (95 % CI) Pa P
The total group CC vs. CT+TT 0.69(0.19,2.53) 0.09 0.57
CC+CT vs. TT 0.75(0.06,9.93) 0.01 0.82
CC vs. TT 0.75(0.06,9.93) 0.01 0.82
C vs. T 0.77(0.22,2.62) 0.002 0.67
The subgroup of more than 5 months CC vs. CT+TT 0.33(0.11,0.98) 0.89 0.05
CC+CT vs. TT 0.30(0.12,0.75) 0.93 0.01
CC vs. TT 0.20(0.06,0.70) 0.55 0.01
C vs. T 0.42(0.23,0.75) 0.94 0.004
ap value of Q-test for heterogeneity test
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because of the variables listed above, the association
might have been biased.
Despite the proven efficacy, large inter-individual
variability exists in the risk of adverse effects in patients
on statins. Muscle toxicity is a relatively common ad-
verse effect, occurring in 1–5 % of cases [31, 32]. Severe
muscle toxicity is rare but represents a significant source
of mortality [33]. This toxicity sometime appears to be
dose-dependent, with higher levels of statins conferring
higher overall risk. Moreover, clinicians should take into
consideration a series of other potential risk factors (i.e.,
female, advanced age, diabetes mellitus, hypothyroidism
and vitamin D deficiency) [34]. In our research, by dif-
ferent treatment protocol, three studies with myopathy
are included. This was the first meta-analysis on the
relationship between the polymorphism and statin-
associated muscle toxicity. The four models of poly-
morphism were all associated with the risk of muscle
toxicity when patients were treated with statins for more
than 5 months. Thus, the treatment duration may influ-
ence the safety of statin treatment. Given that limited
studies were included, the results should be interpreted
with caution, and further larger studies should be
performed.
Statins reduce the risk of major vascular events in a
linear fashion, with a 20 % risk reduction for every
1 mmol/L decrease in low-density-lipoprotein cholester-
ol(LDL-C) [35]. Although an association exists between
the ABCB1 C3435T polymorphism and cholesterol-
lowering therapy, more attention has been paid to the
interaction between SNPs and other factors. Numerous
basic pharmacogenomics studies have revealed that can-
didate genes, such as CETP, HMGCR, SLCO1B1, ABCB1,
and PCSK9,and their polymorphisms may represent
pharmacogenomics biomarkers for predicting statin
treatment outcomes [8]. One study evaluated the effect
of the ABCB1 haplotypes (1236C>T, 2677G>A/T and
3435C>T) on TC and LDL-C responses to simvastatin
and demonstrated a reduction in the T–non-G–T haplo-
type frequency in patients with myalgia compared with
the non-ADR group (P = 03) [10]. Thus, various SNPs
coexisting in the same or different genes might be related
to cholesterol-lowering therapy while on statin therapy,
and attention should be paid to gene-gene interactions,
including SLCO1B1 or PCSK9 with ABCB1 C3435T.
Both genetic and environmental factors influence the
lipid-lowering effect of statins. For example, smokers and
patients with hypertension exhibit smaller decreases in
Fig. 5 Funnel plots of the meta-analysis of the relationship between the ABCB1 C3435T polymorphism and HDL-C change upon statin treatment.
Comparison: CC vs. CT+TT
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LDL-C in response to statin treatment [36]. Furthermore,
some studies have demonstrated that statins may be less
effective in HIV-infected individuals, possibly as a result
of their inherent viral resistance to statins or to highly
active antiretroviral therapy [37]. Furthermore, drugs,
such as amiodarone [38], and inflammation [39] may lead
to a poor response to statin due to the decline in LDL-R
protein [40]. In this meta-analysis, owing to the small
population size as well as the inconsistent stratification in
environmental exposures, further detection of the gene-
environment interaction could not be performed. There-
fore, more sophisticated gene-gene and gene-environment
interactions should be included in a future analysis to ob-
tain a more comprehensive understanding.
If a patient is highly resistant or intolerant to statin
treatment, especially for those with genetic susceptibility
(e.g., those with certain ABCB1 genotypes), there are
several other treatment possibilities. One such drug is
ezetimibe, which is a selective inhibitor of dietary and
biliary cholesterol absorption at the brush border of the
intestine acting that targetsNPC1L1 [41]. The study
IMPROVE-IT evaluated the potential effect of ezetimibe
on major cardiovascular (CV) events and reported a
clear benefit from combination treatment with simvastatin
and ezetimibe in patients with acute coronary syndrome
and low LDL-C [42]. Furthermore, researchers have re-
cently begun to focus on another type of lipid-lowering
drug based on PCSK9 (proprotein convertase subtilisin-
kexin type 9) inhibition by a monoclonal antibody, such as
alirocumab and evolocumab; phase III clinical trials have
recently been initiated. Two recent studies demonstrated
that alirocumab or evolocumab, when added to statin
therapy, significantly reduced LDL-C levels and reduced
the incidence of cardiovascular events [43, 44]. PCSK9 in-
hibition may represent an option for patients who are
statin-intolerant or whose LDL‑C level remains high des-
pite maximal statin therapy with less adverse effects [45].
The above treatment options may be well suited for
patients who respond poorly to statins owing to their
ABCB1 genotypes and provide fresh insight into the lipid-
lowering treatment; however, substantial trails should be
arranged for further assessment.
Although considerable efforts were put forth in our
study design, there were some inherent limitations. First,
the number of studies included is limited, especially with
respect to the information on the risk of myopathy in
patients treated with statin. Thus, the conclusion should
be interpreted with caution. Moreover, some detailed
Fig. 6 Funnel plots of the meta-analysis of the relationship between the ABCB1 C3435T polymorphism and LDL-C change upon statin treatment.
Comparison: CC vs. TT
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information such as the age and sex of the patients were
not available in some studies, and the studies primarily
focused on patients in Latin America, all of which fur-
ther limit our assessment. Furthermore, gene-gene or
gene-environment interactions, can influence the clinical
characteristics, and genotyping methods may affect the
results. The above elements can be controlled more
effectively through a separate analysis of distinct vari-
ables to which we did not have access. And we also
need to promote the “clinical” value of the report widely
since limited hospital has carried out the genotyping
methods.
Conclusion
In summary, this meta-analysis indicated that decreases
in LDL-C as well as TC levels upon statin treatment were
associated with the ABCB1 C3435T homozygous vari-
ation, and people with the CC+CT genotype were more
likely to exhibit elevated serum HDL-C. In addition,
statin treatment for more than 5 months increased the
risk of muscle toxicity. However, additional studies are
needed to address an advanced empirical approach, and
standardized stratification in further tasks is warranted to
validate our findings.
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